Latest News by Industry
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $129.6 million in its first quarter.
The Cambridge, Massachusetts-based company said it had a loss of $2.15 per share.
The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $2.66 per share.
The cancer drug developer posted revenue of $63.3 million in the period, also beating Street forecasts. Ten analysts surveyed by Zacks expected $42.7 million.
Blueprint Medicines shares have increased 18% since the beginning of the year. The stock has dropped 17% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a BPMC">Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC